Effectiveness of the Information Technology-Aided Program of Relapse Prevention in Schizophrenia (ITAREPS): A Randomized, Controlled, Double-Blind Study

被引:58
|
作者
Spaniel, Filip [1 ]
Hrdlicka, Jan [2 ]
Novak, Tomas [1 ]
Kozeny, Jiri [1 ]
Hoeschl, Cyril [1 ]
Mohr, Pavel [1 ]
Motlova, Lucie Bankovska [1 ]
机构
[1] Charles Univ Prague, Fac Med 3, Prague Psychiat Ctr, Ctr Neuropsychiat Studies, Prague 18103 8, Czech Republic
[2] Czech Tech Univ, Fac Elect Engn, Dept Cybernet, CR-16635 Prague, Czech Republic
关键词
schizophrenia; psychotic disorders; relapse prevention; hospitalizations; antipsychotic medication; information technology; FOLLOW-UP; THERAPY; PREDICTION; SYMPTOMS; EPISODE; COSTS; SIGNS;
D O I
10.1097/01.pra.0000416017.45591.c1
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose. To evaluate the effectiveness of the Information Technology-Aided Program of Re lapse Prevention in Schizophrenia (ITAREPS). Methods. Relapse-prone outpatients with schizophrenia or schizoaffective disorder were randomized to the active (n = 75) or control group (n = 71). In the active arm, according to the protocol, investigators were prompted to increase the antipsychotic dose upon occurrence of a pharmacological intervention requiring event (PIRE) detected by ITAREPS. Results. Intention-to-treat (ITT) analysis found no between-group difference in the hospitalization-free survival rate at 12 months. However, the trial suffered from high non-adherence of investigators in the active group, with no antipsychotic dose increase in 61% of PIREs. Furthermore, Cox regression analysis showed a 11-fold increased risk of hospitalization in the absence of pharmacological intervention following a PIRE (hazard ratio [HR] = 10.8; 95% confidence interval [CI] 1.4-80.0; p = 0.002). Therefore, a post-hoc as-treated analysis was performed, which demonstrated a nine-fold reduction in the risk of hospitalization in ITAREPS Algorithm-Adherers (IAAs, n = 25) compared with the ITAREPS Non-interventional group (INIs, n = 70; Kaplan-Meier survival analysis, HR = 0.11, 95% CI 0.05-0.28, p = 0.009; number needed to treat [NNT] = 4, 95% CI 3-10). A significant difference in favor of the IAA group was seen in the number of inpatient days (p < 0.05) and costs (p < 0.05). Conclusion. Future ITAREPS trials should target the underlying mechanisms that cause low investigator adherence to the program. Trial registration: Clinical Trials NCT00712660 (Journal of Psychiatric Practice 2012; 18: 269-280)
引用
收藏
页码:269 / 280
页数:12
相关论文
共 50 条
  • [31] Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia
    Mackle, M.
    Snow-Adami, L.
    Zhao, J.
    Szegedi, A.
    Panagides, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S543 - S543
  • [32] Long-Term Cariprazine Treatment for the Prevention of Relapse in Patients with Schizophrenia: Additional Analysis from a Randomized, Double-Blind, Placebo-Controlled Trial
    Durgam, Suresh
    Earley, Willie
    Li, Rui
    Li, Dayong
    Lu, Kaifeng
    Laszlovszky, Istvan
    Edwards, John
    Nasrallah, Henry
    Fleischhacker, W.
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S380 - S381
  • [33] Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia
    Cooper, SJ
    Butler, A
    Tweed, J
    Welch, C
    Raniwalla, J
    PSYCHOPHARMACOLOGY, 2000, 150 (03) : 237 - 243
  • [34] Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia
    S.J. Cooper
    A. Butler
    J. Tweed
    C. Welch
    J. Raniwalla
    Psychopharmacology, 2000, 150 : 237 - 243
  • [35] A randomized double-blind study of quetiapine and risperidone in the treatment of schizophrenia
    Zhong, K
    Harvey, P
    Brecher, M
    Sweitzer, D
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 508 - 508
  • [36] A randomized, double-blind study of quetiapine and risperidone in the treatment of schizophrenia
    Zhong, K
    Harvey, P
    Brecher, M
    Sweitzer, D
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S232 - S232
  • [37] Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study
    Hough, David
    Gopal, Srihari
    Vijapurkar, Ujjwala
    Lim, Pilar
    Morozova, Margarita
    Eerdekens, Marielle
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 285S - 286S
  • [38] Olanzapine and risperidone in schizophrenia: A randomized double-blind crossover study
    Irwin, J
    Moses, SN
    Edgar, JC
    Torres, F
    Thoma, RJ
    Hanlon, FM
    Anderson, L
    Weisend, MP
    Miller, GA
    Tuason, VB
    Canive, JM
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 286 - 286
  • [39] Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism -: A double-blind, placebo-controlled study
    Kiefer, F
    Jahn, H
    Tarnaske, T
    Helwig, H
    Briken, P
    Holzbach, R
    Kämpf, P
    Stracke, R
    Baehr, M
    Naber, D
    Wiedemann, K
    ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (01) : 92 - 99
  • [40] Fluoxetine treatment for prevention of relapse of depression in children and adolescents: A double-blind, placebo-controlled study
    Emslie, GJ
    Heiligenstein, JH
    Hoog, SL
    Wagner, KD
    Findling, RL
    McCracken, JT
    Nilsson, ME
    Jacobson, JG
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2004, 43 (11): : 1397 - 1405